Fundz

Fundz Deep Dive

Everything you need to win Aulos Bioscience, Inc. — in one platform.

Who to reach, what to say, and why now on Aulos Bioscience, Inc. — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Aulos Bioscience, Inc. — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Aulos Bioscience Raises $20 Million In Series A Extension Financing From Apple Tree Partners

PRIVATEAug 01, 2023•almost 3 years ago

Amount Raised

$20 Million

LarkspurBiotechnology

Investors

Apple Tree Partners

Description

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced $20 million in Series A extension funding committed by Apple Tree Partners (ATP). The funds will be used to advance Aulos’ lead human monoclonal antibody candidate, AU-007, through its initial Phase 2 clinical study in solid tumor cancers.

Company Information

Company

Aulos Bioscience, Inc.

Location

700 LARKSPUR LANDING CIR

Larkspur, California, United States

About

Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems towards killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.

Related People

Suggested for you
1 contact

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Aulos Bioscience, Inc.'s next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching Aulos Bioscience, Inc.? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demoChoose your plan